�now we know the astonishing truth that some patients are waiting a year or more just to get treatment. it�s simply not good enough.� . taking ustekinumab�a biologic that targets a different aspect of the immune system," gelfand said. .
here are 4 mass. biotechs making noise at the ash conference so far http://lm360.us/Ridell-father-of-Waldridge-from-Ruisbroek?Gallegone=151
elizabeth loder, md, professor of neurology, harvard medical school; chief, division of headache, brigham & women's hospital. .